Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
TIlray Brands, Inc. (TLRY) generates frequent news as a global lifestyle and consumer packaged goods company active across cannabis, beverage, wellness, and entertainment categories. Company updates often highlight developments in its cannabis brands, medical cannabis operations, beverage portfolio, and strategic corporate actions, giving investors and followers insight into how Tilray is executing its multi-category strategy.
News coverage commonly includes financial results and segment performance across cannabis, beverage, wellness, and distribution, as reflected in Tilray’s quarterly earnings releases. These updates may discuss trends in international medical cannabis revenue, Canadian adult-use cannabis sales, and distribution activity through Tilray Pharma. Corporate announcements, such as the implementation of a one-for-ten reverse stock split and related shareholder decisions, are also reported through press releases and SEC filings.
Tilray’s brand and product news provides detail on new launches and category expansion. Recent communications feature Dry January and holiday guides showcasing hemp-derived THC beverages, zero-proof spirits, non-alcoholic beers, and craft beers, as well as cannabis-infused beverages under brands like Mollo and XMG. Other releases focus on innovations in cannabis vapes and concentrates under brands such as Good Supply and Redecan, and curated cannabis gift guides that reflect consumer trends in Canada.
Regulatory and medical developments are another important theme. Tilray Medical has issued statements on U.S. federal cannabis rescheduling and the creation of Tilray Medical USA, outlining a framework for U.S. medical cannabis expansion based on experience in regulated international markets. For readers tracking TLRY, this news stream offers context on how the company responds to policy changes, evolves its brand portfolio, and communicates with shareholders. Bookmark this page to access an organized feed of Tilray’s earnings releases, product announcements, regulatory updates, and other material company news.
Tilray's subsidiary, High Park, has launched Chowie Wowie Gummies in Canada, featuring THC Watermelon and balanced THC/CBD Pineapple Mango flavors. Each gummy contains 2.5mg of THC or a combination of THC and CBD. The affordable price is set at $6.99 per pack. These gummies are vegan, gluten-free, and made from clean ingredients, ensuring a pleasant taste without strong cannabis flavors. The product rollout commenced on September 28, 2020, across provinces including Alberta, British Columbia, and Ontario, with plans for additional flavors in the future.
Tilray (NASDAQ: TLRY) announced encouraging results from a clinical trial led by Australian researchers, demonstrating its GMP-produced cannabis product's potential to reduce chemotherapy-induced nausea and vomiting. The study, published in the Annals of Oncology, noted that 25% of patients using medicinal cannabis experienced no vomiting or nausea, compared to 14% of those on a placebo. Following this pilot phase with 81 participants, a larger trial will begin, recruiting an additional 170 participants to assess effectiveness further.